An interventional study of BFR-CYC 50% peak / 50% AOP (exhaustive) and BFR-CYC 3x2min in COPD, sponsored by University of Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by University of Zurich · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Pulmonary Disease, Chronic Obstructive by University of Zurich — 1 open to participants now, 3 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University of Zurich.
Among the 39 studies in Pulmonary Disease, Chronic Obstructive by University of Zurich, this one is the 29th largest by planned enrollment of the 33 interventional ones that give a count, is the only one that started in 2022, is one of 17 with no phase, and was the 35th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 39 studies in Pulmonary Disease, Chronic Obstructive by University of Zurich is open now, in 1 country.
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 69 across the 33 interventional studies, 158 across the 6 observational. Of the 32 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Zurich is the lead sponsor of 1,051 studies on the registry; 134 are open to participants now.
1 of the studies in Pulmonary Disease, Chronic Obstructive by University of Zurich that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05163600University of ZurichThe Acute Cardiorespiratory Response to Blood-flow Restricted Versus Traditional Exercise Training Regimens (CaRe BFR) | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies in Pulmonary Disease, Chronic Obstructive by University of Zurich, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators hypothesize that BFR exercise regimens result in a different acute cardiorespiratory response pattern compared to traditional exercise regimens. Furthermore, the investigators hypothesize that these patterns differ between healthy participants and participants with COPD.
Regarding secondary objective, the investigators hypothesize that BFR results in lower blood pressure responses compared to traditional exercise training in both healthy and COPD participants.
Detailed Description
This study investigates the acute physiological and perceptual responses to blood flow restriction (BFR) exercise compared with conventional endurance and resistance exercise in both patients with chronic obstructive pulmonary disease (COPD) and healthy individuals. The study consists of multiple experimental arms using randomized crossover designs to enable within-subject comparisons across exercise modalities and conditions.
Endurance Exercise - COPD Participants (Exhaustive Protocol)
Patients with COPD will complete three cycling exercise conditions in a randomized, crossover design:
Blood Flow Restriction Cycling (BFR-CYC)
Continuous Cycling (CONT-CYC)
Interval Cycling (INT-CYC)
All sessions will be performed on a cycle ergometer under standardized laboratory conditions, including a warm-up followed by the respective protocol. Exercise will be performed to symptom limitation (volitional exhaustion) unless predefined safety criteria are reached.
BFR-CYC: Continuous cycling at 50% peak work rate (PWR) with bilateral thigh cuffs inflated to 50% limb occlusion pressure (LOP). A maximum duration of 30 minutes is applied as a safety limit.
CONT-CYC: Continuous cycling at 65% PWR until symptom limitation.
INT-CYC: Interval cycling with repeated bouts at 80% PWR, interspersed with recovery periods at 50% PWR, until symptom limitation.
During all sessions, cardiorespiratory parameters (ventilation, oxygen uptake, carbon dioxide production), muscle oxygenation (NIRS), blood lactate, hemodynamic responses, and perceptual responses (dyspnea, perceived exertion) will be continuously measured.
Endurance Exercise - COPD and Healthy Participants (Fixed-Duration Protocol)
Both COPD patients and healthy participants will complete two endurance exercise conditions in a randomized, crossover design:
Blood Flow Restriction Cycling (BFR-CYC)
Non-BFR Control Cycling
All sessions will be conducted under standardized laboratory conditions on a cycle ergometer. Exercise will follow a fixed-duration protocol and will not be performed to volitional exhaustion, unless predefined safety criteria require early termination.
BFR-CYC: Three intervals of 2 minutes at 50% PWR, separated by 1-minute recovery periods, with bilateral thigh cuffs inflated to 50% LOP during exercise intervals.
Control: Time- and structure-matched protocol (3 × 2 minutes) without blood flow restriction at 65% PWR, with identical recovery periods.
During all sessions, cardiorespiratory, hemodynamic, and perceptual responses (dyspnea, perceived exertion) will be continuously measured.
Resistance Exercise - COPD and Healthy Participants (BFR vs Control, Fixed Protocol)
Both COPD patients and healthy participants will complete two resistance exercise conditions in a randomized, crossover design:
Blood Flow Restriction Resistance Exercise (BFR-RE)
Non-BFR Control Resistance Exercise
All sessions will be performed on a leg press device under standardized laboratory conditions. Exercise will follow a fixed set and repetition scheme and will not be performed to volitional exhaustion, unless predefined safety criteria require early termination.
BFR-RE: Unilateral right-leg press at 40% of one-repetition maximum (1RM) with cuffs inflated to 80% LOP. Protocol: 4 sets (30-15-15-15 repetitions).
Control: Bilateral leg press at 40% 1RM, 3 sets of 15 repetitions, without blood flow restriction.
During all sessions, cardiorespiratory, hemodynamic, and perceptual responses will be continuously measured.
Resistance Exercise - Healthy Participants (LOP Comparison Arm)
Healthy participants will complete two BFR resistance exercise conditions in a randomized, crossover design:
BFR at 40% LOP
BFR at 80% LOP
All sessions will be conducted on a leg press device under standardized laboratory conditions. Pneumatic cuffs will be applied to the proximal thigh of the right leg.
Participants will perform unilateral right-leg press exercise at 40% 1RM using a standardized protocol of 4 sets (30-15-15-15 repetitions) with fixed rest intervals. The protocol will be completed as prescribed (not to volitional exhaustion) unless predefined safety criteria require early termination.
Neuromuscular function will be assessed using maximal voluntary contraction (MVC) of the knee extensors measured before and immediately after exercise. Voluntary activation will be evaluated using the twitch interpolation technique with supramaximal electrical stimulation.
Inclusion and exclusion for the healthy participants are defined by the following criteria.
Inclusion criteria:
Exclusion criteria:
Inclusion and exclusion for the participants are defined by the following criteria.
Inclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Both COPD patients and healthy participants will complete two endurance exercise conditions in a randomized, crossover design: * Blood Flow Restriction Cycling (BFR-CYC) * Non-BFR Control Cycling BFR-CYC: Three intervals of 2 minutes at 50% PWR, separated by 1-minute recovery periods, with bilateral thigh cuffs inflated to 50% LOP during exercise intervals. Control: Time- and structure-matched protocol (3 × 2 minutes) without blood flow restriction at 65% PWR, with identical recovery periods.
Other: BFR-CYC 3x2min
Both COPD patients and healthy participants will complete two resistance exercise conditions in a randomized, crossover design: * Blood Flow Restriction Resistance Exercise (BFR-RE) * Non-BFR Control Resistance Exercise BFR-RE: Unilateral right-leg press at 40% of one-repetition maximum (1RM) with cuffs inflated to 80% LOP. Protocol: 4 sets (30-15-15-15 repetitions). Control: Bilateral leg press at 40% 1RM, 3 sets of 15 repetitions, without blood flow restriction.
Other: BFR Resistance 80% LOP
Patients with COPD will complete three cycling exercise conditions in a randomized, crossover design: * Blood Flow Restriction Cycling (BFR-CYC) * Continuous Cycling (CONT-CYC) * Interval Cycling (INT-CYC)
Other: BFR-CYC 50% peak / 50% AOP (exhaustive)
Healthy participants will complete two BFR resistance exercise conditions in a randomized, crossover design: * BFR at 40% LOP * BFR at 80% LOP Participants will perform unilateral right-leg press exercise at 40% 1RM using a standardized protocol of 4 sets (30-15-15-15 repetitions) with fixed rest intervals. The protocol will be completed as prescribed (not to volitional exhaustion) unless predefined safety criteria require early termination.
Other: BFR REsistance 48% vs. 80% LOP
BFR-CYC: Continuous cycling at 50% peak work rate (PWR) with bilateral thigh cuffs inflated to 50% limb occlusion pressure (LOP). A maximum duration of 30 minutes is applied as a safety limit.
BFR-CYC: Three intervals of 2 minutes at 50% PWR, separated by 1-minute recovery periods, with bilateral thigh cuffs inflated to 50% LOP during exercise intervals.
BFR-RE: Unilateral right-leg press at 40% of one-repetition maximum (1RM) with cuffs inflated to 80% LOP. Protocol: 4 sets (30-15-15-15 repetitions).
* BFR at 40% LOP * BFR at 80% LOP All sessions will be conducted on a leg press device under standardized laboratory conditions. Pneumatic cuffs will be applied to the proximal thigh of the right leg. Participants will perform unilateral right-leg press exercise at 40% 1RM using a standardized protocol of 4 sets (30-15-15-15 repetitions) with fixed rest intervals. The protocol will be completed as prescribed (not to volitional exhaustion) unless predefined safety criteria require early termination.
Endurance Exercise:(Fixed-Duration Protocol):
Minute ventilation (VE) will be continuously assessed during cycling exercise across all conditions to evaluate ventilatory demand.
Time frame: Continuously during exercise and at end of exercise, with recovery measurements obtained within 4 minutes post-exercise
Resistance Exercise - Healthy Participants (LOP Comparison Arm): Within-subject difference change in Maximal Voluntary Contraction (MVC)
Maximal voluntary contraction (MVC) of the knee extensors will be assessed before and immediately after unilateral leg press exercise performed with blood flow restriction at 40% and 80% limb occlusion pressure (LOP). MVC will be measured using an isometric setup, and voluntary activation will be evaluated using the twitch interpolation technique with supramaximal electrical stimulation. The primary outcome is the change in MVC from pre- to post-exercise, reflecting exercise-induced neuromuscular fatigue.
Time frame: Pre-exercise and immediately post-exercise (within minutes after completion of the exercise protocol)
Endurance Exercise - COPD Participants (Exhaustive Protocol): Within-subject difference in maximal minute ventilation (VE) between BFR and traditional exercise regimens
Minute ventilation (VE) will be continuously assessed during cycling exercise across all conditions to evaluate ventilatory demand and response.
Time frame: Continuously during exercise, at end of exercise (peak value), and within 4 minutes post-exercise
Resistance Exercise:(Healthy and COPD): Ventilatory Response (Ventilation, VE)
Minute ventilation (VE) will be continuously assessed during cycling exercise across all conditions to evaluate ventilatory demand.
Time frame: Continuously during exercise and at end of exercise, with recovery measurements obtained within 4 minutes post-exercise
Resistance Exercise - Healthy Participants (LOP Comparison Arm): Muscle Oxygenation (NIRS)
Muscle oxygenation of the knee extensors will be continuously assessed using near-infrared spectroscopy (NIRS) during unilateral leg press exercise performed with blood flow restriction at 40% and 80% limb occlusion pressure (LOP). Parameters such as tissue oxygen saturation will be analyzed to evaluate local muscular oxygenation responses.
Time frame: Continuously during exercise and immediately post-exercise
Resistance Exercise - Healthy Participants (LOP Comparison Arm): Perceived Exertion / Dyspnea (Borg Scale)
Perceived exertion will be assessed using the Borg rating of perceived exertion (RPE) scale during cycling exercise. Perceived breathlessness will be assessed using the Borg dyspnea scale during exercise.
Time frame: At baseline (pre-exercise), after each set, immediately post-exercise, and at 2 and 4 minutes post-exercise
Endurance Exercise - COPD Participants (Exhaustive Protocol): Cardiorespiratory Response (Vo2 , VCO2)
Oxygen uptake (VO₂) will be continuously measured during cycling exercise performed under three conditions (BFR-CYC, CONT-CYC, INT-CYC) to symptom limitation. The primary outcome will be the peak VO₂ achieved at end of exercise, reflecting maximal cardiorespiratory response. Carbon dioxide production (VCO₂) will be continuously measured during exercise to assess metabolic and ventilatory responses.
Time frame: Continuously during exercise and at end of exercise, with recovery measurements obtained within 4 minutes post-exercise
Endurance Exercise - COPD Participants (Exhaustive Protocol):NIRS
Muscle oxygenation will be assessed using near-infrared spectroscopy (NIRS) during cycling exercise to evaluate local muscular oxygenation under BFR and non-BFR conditions.
Time frame: Continuously during exercise and at end of exercise, with recovery measurements obtained within 4 minutes post-exercise
Endurance Exercise - COPD Participants (Exhaustive Protocol): Blood Lactate Concentration
Capillary blood lactate concentration will be measured to assess metabolic stress induced by the different exercise conditions.
Time frame: At baseline (pre-exercise) at peak and 3 min wpost-exercise
Endurance Exercise - COPD Participants (Exhaustive Protocol): Perceived Exertion and Dyspnea (Borg Scale)
Perceived exertion will be assessed using the Borg rating of perceived exertion (RPE) scale during cycling exercise. Perceived breathlessness will be assessed using the Borg dyspnea scale during exercise.
Time frame: At baseline (pre-exercise), during exercise (at regular intervals), at end of exercise, and within 4 minutes post-exercise
Endurance Exercise - COPD Participants (Exhaustive Protocol): Exercise Tolerance (Time to Exhaustion)
Exercise tolerance will be defined as the time from the start of exercise to symptom limitation (volitional exhaustion).
Time frame: During exercise (recorded at end of exercise)
Endurance Exercise:(Fixed-Duration Protocol): Cardiorespiratory Response (Vo2 , VCO2)
Carbon dioxide production (VCO₂) will be continuously measured during exercise to assess metabolic and ventilatory responses Oxygen uptake (VO₂) will be continuously measured during cycling exercise performed under two conditions. The primary outcome will be the peak VO₂ achieved at end of exercise, reflecting maximal cardiorespiratory response.
Time frame: Continuously during exercise and at end of exercise, with recovery measurements obtained within 4 minutes post-exercise
Endurance Exercise:(Fixed-Duration Protocol): Borg Scale (Dyspnea/Perceived Exertion)
Perceived exertion will be assessed using the Borg rating of perceived exertion (RPE) scale during cycling exercise. Perceived breathlessness will be assessed using the Borg dyspnea scale during exercise.
Time frame: At baseline (pre-exercise), during exercise (at regular intervals), at end of exercise, and within 4 minutes post-exercise
Resistance Exercise:(Healthy and COPD): Cardiorespiratory Response
Oxygen uptake (VO₂) will be continuously measured during cycling exercise performed under two conditions. Carbon dioxide production (VCO₂) will be continuously measured during exercise to assess metabolic and ventilatory responses.
Time frame: Continuously during exercise and at end of exercise, with recovery measurements obtained within 4 minutes post-exercise
Resistance Exercise:(Healthy and COPD): Dyspnea (Borg Scale/ Perceived Exertion )
Perceived exertion will be assessed using the Borg rating of perceived exertion (RPE) scale during cycling exercise. Perceived breathlessness will be assessed using the Borg dyspnea scale during exercise.
Time frame: At baseline (pre-exercise), during exercise (at regular intervals), at end of exercise, and within 4 minutes post-exercise
Plan to share: No
Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 55 months is above that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →